Recall Alert
| DRAP Alert No | No I/S/07-25-51 |
| Action Date | 29 July, 2025. |
| Target Audience | – National Regulatory Field Force. – Pharmacists and Chemists in Distribution, Pharmacies and Medical Stores – Healthcare Professionals – Physicians, Pharmacists, and Nurses at hospitals and clinics – General Public |
| Problem / Issue | Central Drugs Laboratory Karachi informed Drug Regulatory Authority of Pakistan that the samples of below mentioned Medical Devices have been reported as ‘Substandard’. |
Therapeutic Goods (s) Affected: –
| Product Names | Batch Details | Manufactured by | Test Results |
|---|---|---|---|
| ZINDAGI Auto Disable Syringe 5ml (MDMR-000117) | 5-01E-25 | M/s Al-Badar Manufacturing (Pvt.) Ltd. Gadoon Amazai KPK (ELM-0029) | ‘Substandard’ on the basis of Sterility Test. |
| Ultra Fine SMD Painless Syringe 5ml (MDMR-000229) | 5053CE | M/s Sehat Medical Device (Pvt.) Ltd, Lahore. (ELM-0065) | ‘Substandard’ on the basis of Sterility Test & description test (The clear visible black particles found in the barrel of syringe). |
| Ultra Fine SMD Painless Syringe 3ml (MDMR-000229) | 3022CD | M/s Sehat Medical Device (Pvt.) Ltd, Lahore. (ELM-0065) | ‘Substandard’ on the basis of Sterility Test & description test (The clear visible black particles found in the barrel of syringe). |
| Risk Statement: | Use of substandard syringes, in invasive or intravenous procedures, poses a significant risk of introducing microbial contaminants into the patient’s body, which may result in localized infections, abscesses, or life-threatening systemic infections, particularly in immunocompromised individuals. |
| Action Initiated | – The regulatory field force of DRAP and Provincial Drug Control departments has been directed to immediately conduct market surveys for detection and removal of these products from the market. – All pharmacists and chemists working at distributors and pharmacies should immediately check their stocks and stop supplying these products. The remaining stocks should be quarantined, and the information of their supplier should be immediately provided to their area drug inspector to ensure the removal of falsified product. –Distributors and pharmacies are advised to be vigilant and report any suspected batch of the product(s) in the supply chain to the DRAP using the online form, or by Email at gsms∂dra.gov.pk. –Regulatory field force of all federating units (DRAP, Provincial Health Departments, and States) has also increased the surveillance in the market to ensure the effective recall of defective product(s). |
| Advice for Healthcare Professionals | DRAP requests to enhance vigilance within the supply chains of institutions/pharmacies/healthcare facilities likely to be affected by this defective batch of the product. -Adverse reactions or quality problems experienced with this product may be reported to the National Pharmacovigilance Centre(NPC), DRAP using the Adverse Event Reporting Form or online through this link. -Please click here for further information on problem reporting to DRAP. |
| Advice for Consumers | -Consumers should stop using these product bearing the affected batch number(s). They shall contact their physician or healthcare provider(s) if they have experienced any problem that may be related to using this product. -All therapeutic products must be obtained from authorized licensed pharmacies /outlets. Their authenticity and condition should be carefully checked. If you have any doubts, please seek advice from your pharmacist. |